Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904028 · ClinicalTrials.gov registry record · Phase 3
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
A Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05904028 is a Phase 3 study of Neovascular Age-related Macular Degeneration that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 600 participants, above the 390-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05904028, a Phase 3 study of Neovascular Age-related Macular Degeneration, is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Conditions Studied
Interventions
- DRUG Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
- DEVICE Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
Study Locations (20)
Florida
- National Ophthalmic Research Institute - Fort Myers
- National Ophthalmic Research Institute - Fort Myers
- University of Florida- Jacksonville - Jacksonville
- Florida Retina Institute, James A. Staman, MD, PA- Jacksonville - Jacksonville
- Argus Research Center, Inc - Naples
- Southeast Eye Institute, P.A. dba Eye Associates of Pinellas - Pinellas Park
- Retina Associates of Sarasota - Sarasota
- Sarasota Retina Institute - Sarasota
- Retina Associates of Florida, LLC - Tampa
California
- Kent W. Small, MD, AMC - Glendale
- Loma Linda University - Loma Linda
- East Bay Retina Consultants, Inc. - Oakland
- Kaiser Permanente - Oakland - Oakland
- Southern California Desert Retina Consultants, Inc. - Palm Desert
- UC Davis Health Eye Center - Sacramento
- Macula Retina Vitreous Institute - Torrance
- Bay Area Retina Associates A Medical Group - Walnut Creek
Georgia
- Southeast Retina Center, P.C. - Augusta
- Thomas Eye Group - Sandy Springs
Connecticut
- Retina Consultants - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05904028
The ClinicalTrials.gov registry entry for NCT05904028 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 390-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (54% higher). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule is the first listed.
NCT05904028 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05904028 about?
NCT05904028 is a clinical study titled "Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD". Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
What is the current status of trial NCT05904028?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2023-11-09. Estimated completion is 2027-07-30.
What conditions does trial NCT05904028 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05904028?
The interventions under investigation include: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule (DRUG), Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule (DEVICE).
Who is sponsoring clinical trial NCT05904028?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05904028 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
Extension Study for the Port Delivery System With Ranibizumab (Portal)
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.